Vanguard Group Inc. Decreases Stock Position in CRISPR Therapeutics AG $CRSP

Vanguard Group Inc. cut its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.1% in the 4th quarter, HoldingsChannel reports. The fund owned 2,268,394 shares of the company’s stock after selling 96,251 shares during the quarter. Vanguard Group Inc.’s holdings in CRISPR Therapeutics were worth $118,955,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Thurston Springer Miller Herd & Titak Inc. boosted its stake in shares of CRISPR Therapeutics by 196.9% during the fourth quarter. Thurston Springer Miller Herd & Titak Inc. now owns 576 shares of the company’s stock valued at $30,000 after purchasing an additional 382 shares during the period. Optiver Holding B.V. increased its stake in shares of CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company’s stock worth $33,000 after buying an additional 210 shares during the period. Strategic Advocates LLC purchased a new position in shares of CRISPR Therapeutics in the third quarter worth $34,000. Strategic Wealth Investment Group LLC bought a new stake in CRISPR Therapeutics during the 2nd quarter valued at $36,000. Finally, Bogart Wealth LLC boosted its position in CRISPR Therapeutics by 333.3% during the 3rd quarter. Bogart Wealth LLC now owns 650 shares of the company’s stock valued at $42,000 after buying an additional 500 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CRSP has been the topic of a number of recent analyst reports. Bank of America cut their price target on shares of CRISPR Therapeutics from $90.00 to $89.00 and set a “buy” rating on the stock in a report on Thursday, January 22nd. Citizens Jmp dropped their target price on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a report on Friday, January 30th. Wall Street Zen raised CRISPR Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Truist Financial upgraded CRISPR Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Morgan Stanley reaffirmed an “underweight” rating and set a $33.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $66.06.

Insider Buying and Selling

In other CRISPR Therapeutics news, insider Naimish Patel sold 3,150 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $48.26, for a total value of $152,019.00. Following the completion of the transaction, the insider owned 13,143 shares in the company, valued at approximately $634,281.18. This represents a 19.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 10,020 shares of the company’s stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $46.78, for a total transaction of $468,735.60. Following the completion of the sale, the chief executive officer directly owned 255,501 shares in the company, valued at $11,952,336.78. This represents a 3.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 51,828 shares of company stock valued at $2,578,097 over the last ninety days. Company insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Trading Down 2.2%

NASDAQ:CRSP opened at $52.83 on Wednesday. The company has a 50-day moving average price of $52.03 and a 200-day moving average price of $54.03. CRISPR Therapeutics AG has a 12 month low of $34.87 and a 12 month high of $78.48. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. The stock has a market cap of $5.10 billion, a price-to-earnings ratio of -8.49 and a beta of 1.74.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($1.28) earnings per share (EPS) for the quarter. CRISPR Therapeutics had a negative net margin of 13,856.54% and a negative return on equity of 25.66%. The company had revenue of $1.46 million for the quarter. Equities analysts predict that CRISPR Therapeutics AG will post -5.07 EPS for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.